Flora

Based in Japan, Flora Co. , Ltd. , d. b.

a. Flora, provides a corporate women’s health support platform, women’s health data–driven service and product development support, and a consumer healthcare app for menstrual, pregnancy, and menopause management. Founded in 2020 in Kyoto, Japan, Flora Co. , Ltd.

, d. b. a. Flora, specializes in digital health solutions, focusing on women’s health across stages such as menstruation, pregnancy, and menopause.

In April 2026, Flora raised JPY 230 million in equity and venture debt funding from Plus Social Investment, Nagase Future Investments, PE&HR and other unspecified investors. The CEO, Ananda Seshadri, oversees the company's strategic direction and growth initiatives. Flora specializes in leveraging FemTech Big Data to empower women in achieving their desired selves across various life stages, including menstruation, pregnancy, and menopause. The company offers a suite of digital applications that utilize generative AI and big data to address health challenges faced by women, from adolescence through menopause.

These applications support users in optimizing their health and well-being while promoting active participation in societal roles. Flora’s services cater to both individuals and businesses, providing data-driven insights and practical support aimed at enhancing health outcomes for both women and men, with a client base that includes healthcare providers and enterprises focused on empowering their workforce. Flora generates revenue through a combination of subscription-based services and partnerships with businesses in the healthcare sector. The firm offers its applications directly to consumers while collaborating with organizations to provide tailored health solutions for their employees.

These transactions typically involve subscription plans for app access, granting users ongoing support and resources. Additionally, Flora engages in B2B partnerships, leveraging their data analytics capabilities to assist companies in developing health-focused products and initiatives, fostering improvements in health and diversity across their client organizations. The April 2026 equity and venture debt funding will be utilized to expand the company's services by enhancing products, scaling personalized healthcare functions, growing its platform and Asian presence, and hiring technical and business talent.